NeOnc Technologies Holdings is trading 7.14% up now at $3.75 in after-hours trading after confirming topline Phase 2a NEO100 data for August 12.
- The company announced second-quarter 2026 results and completed topline analysis of its fully enrolled study in recurrent IDH1-mutant high-grade glioma.
- An investor call is scheduled for 8:30 a.m. Eastern time.
- The imminent clinical readout is a clear company-specific catalyst.